Anaplastic Lymphoma Kinase in Cutaneous Malignancies
AbstractAnaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been implicated in the pathogenesis of a variety of neoplasms. As suggested by its name, ALK was first described as part of a translocation product in cases of anaplastic large-cell lymphoma, with other genetic and cytogenetic ALK mutations subsequently coming to attention in the development of many other hematologic and solid organ malignancies. ALK has now been shown to play a role in the pathogenesis of several cutaneous malignancies, including secondary cutaneous systemic anaplastic large-cell lymphoma (ALCL) and primary cutaneous ALCL, melanoma, spitzoid tumors, epithelioid fibrous histiocytoma, Merkel cell carcinoma, and basal cell carcinoma. The characterization of ALK-positivity in these cutaneous malignancies presents exciting opportunities for utilizing ALK-targeted inhibitors in the treatment of these diseases. View Full-Text
Share & Cite This Article
Cao, S.; Nambudiri, V.E. Anaplastic Lymphoma Kinase in Cutaneous Malignancies. Cancers 2017, 9, 123.
Cao S, Nambudiri VE. Anaplastic Lymphoma Kinase in Cutaneous Malignancies. Cancers. 2017; 9(9):123.Chicago/Turabian Style
Cao, Severine; Nambudiri, Vinod E. 2017. "Anaplastic Lymphoma Kinase in Cutaneous Malignancies." Cancers 9, no. 9: 123.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.